Thrombosis and nitric oxide donor drugs

• References

• 1 Horowitz A, Menice CB, Laporte R. et Mechanisms of smooth muscle contraction. Physiol Rev 1996; 76: 967-1003.
• 2 Moro MA, Russel RJ, Cellek S. et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996; 93: 1480-5.
• 3 Maree A, Fitzgerald D. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: Where are we now?. Semin Vasc Med 2003; 03: 385-90.
• 4 Chakrabarti S, Varghese S, Cox D. et al. Glycoprotein IIb/IIIa Inhibition Enhances Platelet Nitric Oxide Release. Thromb Res. 2004 In Press.
• 5 Moro MA, Darley-Usmar VM, Goodwin DA. et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci U S A 1994; 91: 6702-6.
• 6 Low SY, Sabetkar M, Bruckdorfer KR. et al. The role of protein nitration in the inhibition of platelet activation by peroxynitrite. FEBS Lett 2002; 511: 59-64.
• 7 Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol 2002; 38: 259-69.
• 8 Gori T, Burstein JM, Ahmed S. et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001; 104: 1119-23.
• 9 Vilahur G, Segales E, Casani L. et al. A novel anti-ischaemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb Haemost 2004; 91: 1035-43.